

Intertwining Social and Behavioral Sciences within IMPAACT's HIV treatment and prevention clinical research initiatives

Nicole A. Montañez, MSW¹; Jennifer Libous, MS, CCRP¹; Kenneth Ngure, MPH, EMOD, MSc, PhD²; Jessica Haberer, MD, MS³; Renee Heffron, PhD⁴, Rachel Kidman, PhD⁵; Ellen Townley, MD⁶; Tafadzwa Kasambira, MD, MA, MPH⁶; K Rivet Amico, PhD⁷ for the Social Behavioral Scientific Core

¹FHI 360 Durham, NC/Washington DC, USA; ²Jomo Kenyatta University of Agriculture and Technology (JKUAT), Nairobi, Kenya; ³Massachusetts General Hospital Global Health, Boston, Massachusetts, USA; ⁴The University of Alabama at Birmingham, Birmingham, Alabama, USA; ⁵State University of New York at Stony Brook, Stony Brook, NY, USA; ⁶National Institutes of Health, Bethesda, Maryland, USA; ⁷University of Michigan School of Public Health, Ann Arbor, Michigan, USA

BACKGROUND

- Inception: The Social Behavioral Scientific Core (SBSC) within the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network formed in January 2019.
- SBSC members: experienced in conduct of multi-site clinical trials (CTs) in HIV prevention and care, retention, community engagement, adherence, and social determinants of CT outcomes.
- Achievements: the SBSC established and promoted interdisciplinary connections within the IMPAACT Network through:
 - ✓ conducting proposal reviews;
 - ✓ collaborations with social scientists, epidemiologists, SBS advocates, and HIV specialists within IMPAACT;
 - ✓ consultations on SBS study design and measurement development; and internship support to create SBS resources.

The SBSC increases collaborative growth by 1) creating a database to harmonize tools across studies and 2) designing a series of interdisciplinary talks encompassing varying SBS topics providing space for questions, learning, communication, and connection around SBS.

DESIGN

To connect the dots across interdisciplinary collaborators on processes, agendas, and measurement tools, SBSC members joined IMPAACT's protocol review group and committees (Tuberculosis, HIV Cure, HIV Treatment, Complications & Comorbidities).

This collaborative model connects clinical research stakeholders to accomplish social behavioral science focused outcomes, such as:

- 1) Conducting SBS-focused reviews of research proposals from each IMPAACT committees early in development to identify gaps or improvements for social behavioral study designs, research objectives and outcomes, measures, and/or tools to enhance the scientific rigor of the study.
- 2) Providing expert input to IMPAACT committees to ensure proposals approved for protocol development include appropriate social behavioral components.
- **3)** <u>Delivering ad hoc consultations</u> for study teams on protocols in development and throughout IMPAACT review processes which provide technical guidance on design, recommendations of existing tools or creating new tools for adherence, preferences, beliefs, behaviors, and attitudes towards the product or study implementation.


RESULTS

The SBSC provided collaborative input towards IMPAACT's HIV research through:

- Guidance on study implementation and relevant SBS components
- Monitoring approvals of SBS work
- Hosting an internship for collaboration, tools development, and mentorship
- Identification, recommendation, development, and monitoring measurements of:
 - ✓ adherence objectives
 - ✓ SBS determinants, mediators, and moderators to advance understanding of trial outcomes
 - ✓ participant, caregiver, and health worker preferences, behaviors, and attitudes
 - ✓ acceptability and palatability assessments

SBSC

Operations Within the IMPAACT NETWORK



LESSONS LEARNED

Areas of SBS could impact outcomes, and ultimately regulatory approvals

Networks could advance SBS more efficiently if compendiums of SBS measures are created for easy search and identification of tools

RECOMMENDATIONS

To operationalize SBS work within CT's:

- Embed SBSC members in proposal reviews for early and targeted engagement for highest impact
- Incorporate SBS components early in protocol development
- Maximize study staff training and capacity building, and
- Utilize community input on appropriateness of assessment questions and identifying gaps

DISCUSSION/IMPLICATIONS

A collaborative model provides positive impact at a micro and macro-level.

Micro-level

- ✓ SBSC members on committees and as ad hoc consultants provides: 1) effective and impactful communication through protocol development and 2) ways for interdisciplinary scientific collaboration across the SBSC, committees, and study teams
- ✓ May reduce siloed effects of constricted-scoped study designs by promoting diverse perspectives to co-exist for broader impact to best incorporation strategies

Enhancing collaborations with grassroots efforts and leadership engagement are key to meet in the middle and influence greater change.

Macro-level

- ✓ Ease and value of incorporating SBS into clinical research for others to adopt efficiently for long-lasting positive effects on research outcomes and real-world implications
- ✓ Influences interventions globally through enhanced collaborations and early SBS integration for successful retention and care

ACKNOWLEDGMENTS

Rachael Jeffrey, Mehreen Buksh, IMPAACT Committees: HIV Cure, HIV Treatment, Complications & Co-Morbidities, Tuberculosis, IMPAACT Leadership, and Graeme Hoddinott, Yael Hirsch-Moverman, Nishi Suryavanshi for support and contributions to the SBSC.



For more information, visit <u>impaactnetwork.org</u> and follow us:

Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), all components of the National Institutes of Health (NIH), under Award Numbers UM1AI068632-15 (IMPAACT LOC), UM1AI068616-15 (IMPAACT SDMC) and UM1AI106716-09 (IMPAACT LC), and by NICHD contract number HHSN275201800001I. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Presented at the International SBCC Summit 2022 5 – 9 December 2022